Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset

Despite an improved understanding of the genetic background and the pathomechanisms of amyotrophic lateral sclerosis (ALS) no novel disease-modifying therapies have been successfully implemented in clinical routine. Riluzole still remains the only clinically approved substance in human ALS treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Günther, René, Balck, Alexander, Koch, Jan C., Nientiedt, Tobias, Sereda, Michael, Bähr, Mathias, Lingor, Paul, Tönges, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281550/
https://www.ncbi.nlm.nih.gov/pubmed/28197100
http://dx.doi.org/10.3389/fphar.2017.00017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281550/
https://www.ncbi.nlm.nih.gov/pubmed/28197100
http://dx.doi.org/10.3389/fphar.2017.00017

Ejemplares similares